Secoisolariciresinol Diglucoside Alleviates LPS‐Induced Acute Lung Injury by Inhibiting the NF‐κB/NLRP3 Signaling Pathway
Drug Development Research · 2026
DOI: 10.1002/ddr.70285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Yuanyuan Zhong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gerontology, People's Hospital of Leshan, Leshan, Sichuan, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Acute Lung Injury, NF-kappa B, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Project of Leshan Science and Technology Bureau.
Abstract (Originalsprache)
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are life‐threatening pulmonary disorders with high mortality rates, and effective treatments are currently lacking. Secoisolariciresinol diglucoside (SDG), a plant lignan derived from flaxseed, possesses anti‐inflammatory and antioxidative activities. However, the underlying mechanisms by which SDG ameliorates ALI remain incompletely understood. This study aimed to investigate whether SDG alleviates ALI by modulating the NF‐κB/NLRP3 signaling pathway. For the in vivo study, ALI was induced in mice through intranasal administration of LPS. Key indicators included lung histopathological changes, wet/dry weight ratio (W/D), protein concentration in bronchoalveolar lavage fluid (BALF), oxidative stress markers (MDA, SOD, CAT), the expression of inflammatory cytokines and chemokines (IL‐1β, IL‐18, TNF‐α, CCL2), and the level of NF‐κB/NLRP3 pathway‐related proteins. In vitro experiments using LPS‐stimulated RAW264.7 further explored the effects of SDG on the NF‐κB/NLRP3 pathway. SDG significantly mitigated LPS‐induced lung histopathological damage and nasal mucosal injury, reduced lung W/D ratio and BALF protein, and suppressed oxidative stress. Moreover, SDG downregulated pro‐inflammatory cytokines (IL‐1β, IL‐18, TNF‐α) and macrophage infiltration. It also decreased the expression of N‐κB/NLRP3 pathway‐related proteins. In vitro experiments further confirmed that SDG inhibited the NF‐κB/NLRP3 pathway. SDG effectively alleviates LPS‐induced ALI through its antioxidant, anti‐inflammatory, and NF‐κB/NLRP3 pathway‐inhibiting properties, providing experimental evidence for its potential as a therapeutic agent for ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gerontology, People's Hospital of Leshan, Leshan, Sichuan, China.
- Department of Otolaryngology, People's Hospital of Leshan, Leshan, Sichuan, China.
- Department of Gastroenterology, People's Hospital of Leshan, Leshan, Sichuan, China.
- Department of Gastroenterology, General Hospital of Ningxia Medical University, Yinchuan, China.
- Departement of Otolaryngology and Head and Neck Surgery, People's Hospital of Jiangyou, Jiangyou, Sichuan, China.
Förderung
- Key Research and Development Project of Leshan Science and Technology Bureau
Zitieren
APA
Zhong, Y., Zou, Y., Qu, Z., Zhou, K., Liu, H., Yang, J., Tang, C., Xu, Y., & Wang, Z. (2026). Secoisolariciresinol Diglucoside Alleviates LPS‐Induced Acute Lung Injury by Inhibiting the NF‐κB/NLRP3 Signaling Pathway. Drug Development Research. https://doi.org/10.1002/ddr.70285
Vancouver
Zhong Y, Zou Y, Qu Z, Zhou K, Liu H, Yang J, et al. Secoisolariciresinol Diglucoside Alleviates LPS‐Induced Acute Lung Injury by Inhibiting the NF‐κB/NLRP3 Signaling Pathway. Drug Development Research. 2026. doi:10.1002/ddr.70285
BibTeX
@article{Zhong2026,
author = {Zhong, Yuanyuan and Zou, Yang and Qu, Zhen and Zhou, Kai and Liu, Huijuan and Yang, Jiali and Tang, Chengzhong and Xu, Yuqiang and Wang, Zhen},
title = {Secoisolariciresinol Diglucoside Alleviates LPS‐Induced Acute Lung Injury by Inhibiting the NF‐κB/NLRP3 Signaling Pathway},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70285}
}
EUVIMED